Shinshu University HOMEJAPANESEAccess / Campus Map

Shinshu University Researcher DirectoryShinshu University Researcher Directory

Search by Researcher / Research Field
Search by Category

Ashida Atsuko

Academic OrganizationAcademic Assembly School of Medicine and Health Sciences Institute of MedicineTEL
Education and Research OrganizationUniversity Hospital, Center for Clinical ResearchFAX
PositionAssociate ProfessorMail Address
AddressAsahi 3-1-1 Matsumoto, NaganoWeb site



Research Field
Academic Background
Graduate School
信州大学大学院医学研究科博士課程 , 2009
信州大学医学部 , 1995

博士(医学) , 信州大学


Books, Articles, etc.
分子異常, カレントテラピー:メラノーマ-基礎から最新薬物療法まで-

家族性腫瘍-家族性腫瘍の最新研究動向-:Familial atypical multiple mole melanoma syndrome, 日本臨床 73 増刊号6, 99-102

日本人におけるMAPK系の遺伝子変異率と遺伝子検査の実際, Monthly Book Derma 230 メラノーマ最新情報 , 63-68

最新臨床大腸癌学:抗EGFR抗体薬により皮膚障害とその予防・対策, 日本臨床 73 増刊号4, 612-616

分子標的薬 KITを標的とした治療薬, 皮膚科臨床アセット 17: 皮膚の悪性腫瘍 , 59-64

皮膚悪性腫瘍 チロシンキナーゼ:KIT, 日本臨床 71 71 増刊号4, 134-138

皮膚悪性腫瘍:MAPキナーゼ:NRAS、BRAF、MEK, 日本臨床 71 71 増刊号4, 126-129

Case of annular pustular psoriasis/circinate erythematous psoriasis induced by hydroxychloroquine in a patient with systemic lupus erythematosus: Possible association with CARD-14 mutation.
The Journal of dermatology,48(9):e440-e442 2021(Sep.)
Author:Hirotaka Midorikawa; Yukiko Kiniwa; Akane Minagawa; Kana Osawa; Takushi Shirai; Tasuku Sano; Kenta Nakamura; Atsuko Ashida; Ken-Ichi Ueno; Takuya Takeichi; Masashi Akiyama; Ryuhei Okuyama

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
BMC cancer,21(1):287-287 2021(Mar. 17)
Author:Yukiko Kiniwa; Kenta Nakamura; Asuka Mikoshiba; Atsuko Ashida; Yasuyuki Akiyama; Atsushi Morimoto; Ryuhei Okuyama
Abstract:BACKGROUND: While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood. We examined whether CTCs have potential as biomarkers by checking the number of CTCs, as well as the BRAF genotype of individual CTCs, in melanoma patients undergoing BRAF/MEK inhibitor treatment. METHODS: CTCs were isolated from peripheral blood using a high-density dielectrophoretic microwell array, followed by labeling with melanoma-specific markers (MART-1 and/or gp100) and a leukocyte marker (CD45). The numbers of CTCs were analyzed in fifteen patients with stage 0-III melanoma. Furthermore, changes in CTC numbers were assessed in five patients with stage IV melanoma at four time points during BRAF/MEK inhibitor treatment, and the BRAF genotype was analyzed in CTCs isolated from one patient. RESULTS: We examined CTCs in patients with stage 0-III (five samples per stage: stage 0-I, stage II, and stage III), and detected CTCs even in patients with early disease (stage 0 and I). Interestingly, recurrence occurred in the lymph nodes of one stage I patient 2 years after the detection of a high number of CTCs in the patient's blood. The total number of CTCs in four of five patients with stage IV melanoma fluctuated in response to BRAF/MEK inhibitor treatment, suggesting that CTC number has potential for use as a drug response marker in advanced disease patients. Interestingly, one of those patients had CTCs harboring seven different BRAF genotypes, and the mutated CTCs disappeared upon BRAF/MEK inhibitor treatment, except for those harboring BRAFA598V. CONCLUSIONS: CTCs are present even in the early stage of melanoma, and the number of CTCs seems to reflect patients' responses to BRAF/MEK inhibitor treatment. Furthermore, genetic heterogeneity of BRAF may contribute to resistance to BRAF/MEK inhibitors. Our findings demonstrate the usefulness of CTC analysis for monitoring responses to targeted therapies in melanoma patients, and for understanding the mechanism of drug resistance.

Paraneoplastic pemphigus associated with Waldenström's macroglobulinemia.
The Journal of dermatology,47(5):e200-e201 2020(May)
Author:Takushi Shirai; Yukiko Kiniwa; Norito Ishii; Takashi Hashimoto; Yasushi Senoo; Kazuhisa Urushihata; Atsuko Ashida; Ryuhei Okuyama

Detecting copy number alterations of oncogenes in cell-free DNA to monitor treatment response in acral and mucosal melanoma.
Journal of dermatological science,97(3):172-178 2020(Mar.)
Author:Asuka Mikoshiba; Atsuko Ashida; Kaori Sakaizawa; Yukiko Kiniwa; Ryuhei Okuyama
Abstract:BACKGROUND: Reliable biomarkers are necessary for assessment of treatment responses. Acral and mucosal melanomas are commonly associated with copy number (CN) alterations rather than specific point mutations, with CN alterations inKIT, CDK4, and CCND1 occurring frequently. Cell-free DNA is released to peripheral blood by both normal and tumor cells, and therefore contains the same genetic alterations present in the source tumor. OBJECTIVE: To investigate the usefulness of detecting CN alterations in oncogenes in cell-free DNA for monitoring treatment response in acral and mucosal melanomas. METHODS: We isolated cell-free DNA from peripheral blood and assessed the CN alterations in the cell-free DNA. Using droplet digital PCR, we examined CN alterations ofKIT, CDK4, and CCND1 in tumors from 37 melanoma patients (acral, n = 27; mucosal, n = 10) and peripheral blood from 24 melanoma patients (acral, n = 17; mucosal, n = 7). RESULTS: CN gain was detected in at least one of the genes examined in 62.9 % (17/27) of acral melanomas and 70 % (7/10) of mucosal melanomas. CN gains were also detected in the plasma of some patients. Furthermore, plasma CN ratio was correlated with clinical condition. This correlation was especially clear in patients with high CN ratios in tumors and high tumor burdens. CONCLUSION: Plasma CN ratios may be useful for evaluating treatment responses in patients with acral and mucosal melanoma.

BRAF Mutation Heterogeneity in Melanoma Lesions.
Acta dermato-venereologica,100(1):adv00045 2020(Jan. 30)
Author:Kaori Sakaizawa; Atsuko Ashida; Yukiko Kiniwa; Ryuhei Okuyama

Three cases of squamous cell carcinoma associated with voriconazole treatment
Skin Cancer (Web),35(3) 2020
Author:二瓶達也; 芦田敦子; 翠川央高; 永井史緒; 海野俊徳; 久保仁美; 住昌彦; 木庭幸子; 奥山隆平

Circulating tumor DNA reflects tumor burden independently of adverse events caused by systemic therapies for melanoma
日本癌学会学術総会抄録集(Web),78th(12):P-2343 2019
Author:芦田敦子; 境澤香里; 御子柴飛鳥; 奥山隆平

日本乾癬学会学術大会プログラム・抄録集,34th 2019
Author:佐藤勇樹; 芦田敦子; 牛木淳人; 奥山隆平

Dacarbazine as third-line treatment for malignant melanoma : Retrospective study of three cases
Skin Cancer (Web),33(3) 2019
Author:中村謙太; 芦田敦子; 中村麗那; 木庭幸子; 奥山隆平

日本皮膚科学会雑誌,128(6) 2018

Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Acta dermato-venereologica,97(10):1212-1218 2017(Nov. 15)
Author:Atsuko Ashida; Kaori Sakaizawa; Hisashi Uhara; Ryuhei Okuyama
Abstract:Anti-programmed cell death-1 (anti-PD-1) antibody shows high therapeutic efficacy in patients with advanced melanoma. However, assessment of its therapeutic activity can be challenging because of tumour enlargement associated with intratumoural inflammation. Because circulating tumour DNA (ctDNA) correlates with tumour burden, we assessed the value of ctDNA levels as an indicator of tumour changes. Quantification of ctDNA (BRAFmutant or NRASmutant) levels by droplet digital PCR in 5 patients with BRAF or NRAS mutant melanoma during the treatment course showed dynamic changes corresponding to radiological and clinical alterations. In 3 cases in which the anti-PD-1 antibody was effective, ctDNA levels decreased within 2-4 weeks after treatment initiation. In 2 cases in which the anti-PD-1 antibody was ineffective, ctDNA levels did not decrease after treatment initiation. ctDNA could be a useful biomarker to predict early response to treatment in patients with advanced melanoma treated with anti-PD-1 immunotherapy.

Detection of BRAF(V600K) mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma
Author:Kaori Sakaizawa; Atsuko Ashida; Hisashi Uhara; Ryuhei Okuyama

Detection of BRAFV600K mutant tumor-derived DNA in the pleural effusion from a patient with metastatic melanoma
Clin Chemi Lab Med,55(4):e92-e95 2017(Mar.)
Author:Kaori Sakaizawa, Ashida A, Uhara H , Okuyama R

Distinct phenotype of epidermolysis bullosa simplex with infantile migratory circinate erythema due to frameshift mutations in the V2 domain of KRT5
European Academy of Dermatology and VenereologyActa Derm Venereol ,31(5):e241-e243 2016(Nov.)
Author:Y.Kumagai, N. Umegaki-Arao, T. Sasaki,Y. Nakamura, H. Takahashi, A. Ashida, Y. Tsunemi,M. Kawashima, A. Shimizu, A. Ishiko, K. Nakamura,H. Tsuchihashi, M. Amagai, A. Kubo

Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR.
International journal of clinical oncology,21(5):981-988 2016(Oct.)
Author:Atsuko Ashida; Kaori Sakaizawa; Asuka Mikoshiba; Hisashi Uhara; Ryuhei Okuyama
Abstract:BACKGROUND: BRAF V600E is a common mutation in melanoma, and BRAF inhibitors are effective in treating of BRAF mutation-positive melanoma. DNA carrying this mutation is released from melanoma cells into the circulation. As such, circulating tumor-derived DNA (ctDNA) in peripheral blood represents a novel biomarker for evaluating tumor features in cancer patients. However, ctDNA is present in the peripheral blood at very low levels, which makes the detection of specific mutations in this DNA a challenge. Competitive allele-specific TaqMan PCR (castPCR), a straightforward commercially available assay, is a sensitive technique for quantitating a small amount of DNA. METHODS: The level of BRAF V600E ctDNA was quantified by castPCR in 26 consecutive plasma samples from six melanoma patients. RESULTS: The castPCR assay was performed using a mixture of BRAF V600E DNA and BRAF wild DNA and found to be able to detect BRAF V600E at a fractional abundance of ≥0.5 % in 2- to 10-ng samples of genomic DNA. Cell-free DNA was then extracted from peripheral blood samples collected from six patients with melanoma harboring the BRAF V600E mutation. BRAF V600E ctDNA was detected in three patients, at a fractional abundance of between 1.28 and 58.0 % of total BRAF cell-free DNA. The abundance of BRAF V600E ctDNA correlated with tumor burden, as determined by computed tomography imaging. In two cases, an increase in the level of BRAF V600E ctDNA preceded exacerbation of clinical symptoms. CONCLUSION: The castPCR assay can detect and quantitate small amounts of BRAF V600E ctDNA in samples containing large amounts of BRAF wild cell-free DNA. Thus, we suggest that the castPCR assay is suitable for monitoring ctDNA in the plasma of melanoma patients.

Acquired epidermodysplasia verruciformis associated with human papillomavirus type 47 in a HIV-infected patient.
The Journal of dermatology,43(6):717-8 2016(Jun.)
Author:Atsuko Ashida; Akira Shimizu; Ryuhei Okuyama

Quantitative analysis of the BRAFV600E mutation in circulating tumor-derived DNA using competitive allele-specific TaqMan PCR in melanoma patients
Int J Clin Oncol.,21(5):981-988 2016(May)
Author:Ashida A, Sakaizawa K, Mikoshiba A, Uhara H , Okuyama R

Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash.
Journal of dermatological science,82(1):53-6 2016(Apr.)
Author:Atsuko Ashida; Eisaku Ogawa; Hisashi Uhara; Tomonobu Koizumi; Ryuhei Okuyama

Melanoma with BRAF Mutation in Circulating Cell-free DNA despite no Mutation in the Primary Lesion: A Case Report.
Acta dermato-venereologica,96(1):128-9 2016(Jan.)
Author:Atsuko Ashida; Hisashi Uhara; Asuka Mikoshiba; Kaori Sakaizawa; Naomi Kumagai; Hiroshi Koga; Ryuhei Okuyama

皮膚かたち研究学会学術大会プログラム・抄録集,43rd 2016
Author:皆川茜; 古賀弘志; 境澤香里; 芦田敦子; 宇原久; 奥山隆平

Epidermolysis bullosa simplex with mottled pigmentationの2家系
日本皮膚科学会雑誌,126(6) 2016
Author:久保亮治; 熊谷宜子; 天谷雅行; 芦田敦子; 芦田敦子; 常深祐一郎; 石河晃

幼少期に環状浮腫性紅斑を生じたepidermolysis bullosa simplex with mottled pigmentationの2例
日本皮膚科学会雑誌,126(5) 2016
Author:熊谷宜子; 熊谷宜子; 梅垣知子; 佐々木貴史; 芦田敦子; 常深祐一郎; 川島眞; 中村晃一郎; 石河晃; 天谷雅行; 天谷雅行; 久保亮治

Histopathological improvement of scleroderma induced by paclitaxel in a patient with breast cancer.
The Journal of dermatology,42(12):1198-9 2015(Dec.)
Author:Atsuko Ohashi; Akane Minagawa; Atsuko Ashida; Hiroshi Koga; Hisashi Uhara; Ryuhei Okuyama

Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
Journal of dermatological science,80(1):33-7 2015(Oct.)
Author:Kaori Sakaizawa; Atsuko Ashida; Aya Uchiyama; Takamichi Ito; Yasuhiro Fujisawa; Dai Ogata; Shigeto Matsushita; Kazuyasu Fujii; Satoshi Fukushima; Yoshitsugu Shibayama; Naohito Hatta; Tatsuya Takenouchi; Jiro Uehara; Ryuhei Okuyama; Naoya Yamazaki; Hisashi Uhara
Abstract:BACKGROUND: The importance of the genetic background of melanoma cells to the individual susceptibility to treatment has become apparent. In Caucasians, BRAF mutations are frequently detected in lesions on the skin of younger patients compared to NRAS and KIT mutations. However, clinical and pathological characteristics associated with BRAF, NRAS and KIT mutations have not been fully evaluated in East Asians. OBJECTIVE: To clarify clinical and pathological characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. METHODS: Clinical data were retrospectively collected from 11 hospitals in Japan. BRAF, NRAS and KIT mutations were evaluated with polymerase chain reaction and Sanger sequencing. The relationships between these gene mutations and pathological and clinical findings were analyzed. RESULTS: The number of cases examined was 171 (primary: 135, metastases: 11, paired: 25), and all were Japanese patients. The detection rates of BRAF, NRAS and KIT mutations were 30.4%, 12.3% and 12.9%, respectively. Compared with the wild type, the presence of BRAF mutations was significantly associated with younger age (median, 50.0 years vs. 70.0 years, p<0.001). BRAF mutation was frequently detected in the lesions of the scalp (80%; 4/5), trunk (72.0%; 18/25), extremities (56.7%; 17/30) and neck (44.4%; 4/9), and the least prevalent were the face (22.2%; 2/9), nail (12.5%; 3/24), palm or sole (8.9%; 4/45) and mucosa (0%). NRAS mutations were prevalent in the face (33.3%) and palm or sole (20.0%), and the median age of these patients was 70.5 years. A KIT mutation was observed in the nail apparatus (25%), palm or sole (15.6%) and mucosa (18.2%). The median age of the patients with a KIT mutation was 63.0 years. Heterogeneity of mutations between primary and metastatic lesions was detected in six of 25 cases (24%). Solar elastosis was identified in 12 of 71 cases (15.3%), among which four cases harbored BRAF(V600E) (2 cases), BRAF(V600K), NRAS(Q61K) or NRAS(Q61L), respectively. CONCLUSION: Some clinical characteristics associated with BRAF, NRAS and KIT mutations were observed in Japanese patients, and we observed both similarities to and differences from those of Caucasians. Our findings could provide useful information in efforts to clarify the tumor genesis of malignant melanomas.

日本皮膚科学会雑誌,125(8):1587-1592 2015(Aug.)

An Initial Case Report of a Laparoscopic Spleen-Preserving Distal Pancreatectomy for a Patient with a Pancreatic Metastasis of Malignant Melanoma
The Shinshu medical journal,63(1):19-24 2015(Jan.)
Author:Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Furusawa N , Sakai H, Kitagawa N, Ashida A, Okuyama R, Miyagawa S

皮膚科の臨床,56(13):2169-2172 2014(Dec.)

Toll-like receptor 4 signaling promotes the migration of human melanoma cells.
The Tohoku journal of experimental medicine,234(1):57-65 2014(Sep.)
Author:Yuko Takazawa; Yukiko Kiniwa; Eisaku Ogawa; Aya Uchiyama; Atsuko Ashida; Hisashi Uhara; Yasufumi Goto; Ryuhei Okuyama
Abstract:Immune cell Toll-like receptors (TLRs) recognize conserved microbial components, leading to immune and inflammatory responses. However, TLRs are also expressed in cancer cells, including melanoma cells, which express TLR2-4. TLR4 ligands have received attention as immunotherapies; therefore, we assessed the expression of TLR4 in human melanoma specimens (29 primary lesions and 28 metastatic lesions) representing different types of melanoma. A high percentage (≥ 90%) of melanoma lesions expressed TLR4, as judged by immunohistochemistry. Next, the role of TLR4 in cell proliferation and migration was assessed using the TLR4-positive (TLR4(+)) melanoma cell lines 501mel and 888mel, and TLR4-negative (TLR4(‒)) 928mel melanoma cells. Lipopolysaccharide (LPS), a TLR4 agonist, increased the proliferation of TLR4(+) melanoma cells but not of TLR4(‒) 928mel cells. The proliferation-inducing effect of LPS in 888mel cells was abolished by blockade of TLR4 signaling via treatment with short interfering RNA (siRNA) targeting TLR4 or myeloid differentiation primary response gene 88 (MyD88), a molecule downstream of TLR4. However, knockdown of TLR4 or MyD88 expression did not affect the LPS-induced proliferation of 501mel cells, suggesting that residual TLR4 signaling is sufficient to maintain cell proliferation. By contrast, LPS increased the migration of TLR4(+) melanoma cells, and this effect was substantially inhibited by TLR4 or MyD88 knockdown. Furthermore, TLR4 knockdown decreased cell migration even in the absence of LPS, suggesting the presence of an endogenous TLR4 ligand(s) in melanoma cells. TLR4 signaling may contribute to melanoma progression, and caution should be exercised when using TLR4 ligands as adjuvant therapy for cancer.

5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi.
Journal of dermatological science,73(2):161-3 2014(Feb.)
Author:Ryuhei Uchiyama; Hisashi Uhara; Aya Uchiyama; Eisaku Ogawa; Yuko Takazawa; Atsuko Ashida; Hiroshi Koga; Koichi Hayashi; Yukiko Kiniwa; Ryuhei Okuyama

Successful treatment of rheumatoid vasculitis-associated skin ulcer with a TNF-α antagonist.
International journal of dermatology,53(2):e154-6 2014(Feb.)
Author:Atsuko Ashida; Hiroshi Murata; Yasutomo Mikoshiba; Atsuko Ohashi; Aya Kobayashi; Hiroshi Koga; Hisashi Uhara; Ryuhei Okuyama

Fibrosarcomatous variant of dermatofibrosarcoma protuberans with pancreatic metastasis.
International journal of dermatology,53(2):e140-2 2014(Feb.)
Author:Hiroshi Murata; Atsuko Ohashi; Atsuko Ashida; Hisashi Uhara; Ryuhei Okuyama; Takenari Nakata; Kunihiko Shingu

J Environmental Dermatology and Cutaneous Allergology,8(1):38-42 2014(Jan.)
Author:上條史尚、芦田敦子、 葭矢裕之、佐藤勇樹、小林彩、村田浩、 福澤正男、宇原久、奥山隆平

Coexpression of EpCAM, CD44 variant isoforms and claudin-7 in anaplastic thyroid carcinoma.
PloS one,9(4):e94487 2014
Author:Toshihiro Okada; Teruo Nakamura; Takayuki Watanabe; Naoyoshi Onoda; Atsuko Ashida; Ryuhei Okuyama; Ken-ichi Ito
Abstract:BACKGROUND: Anaplastic thyroid cancer is considered to be one of the most aggressive human malignancies, and the mean survival time after diagnosis is approximately six months, regardless of treatments. This study aimed to examine how EpCAM and its related molecules are involved in the characteristics of anaplastic thyroid carcinoma. METHODOLOGY/PRINCIPAL FINDINGS: Two differentiated thyroid cancer cell lines (TPC-1 and FTC-133), and two anaplastic thyroid cancer cell lines (FRO, ACT-1) were analyzed for expression of CD44 standard isoform (CD44s), CD44 variant isoforms, and EpCAM, and human aldehyde dehydrogenase-1 (ALDH1) enzymatic activity using flow cytometry. CD44s expression was higher in TPC-1 and FTC-133 than in the FRO and ACT-1, whereas ALDH1 activities were higher in FRO and ACT-1 than in TPC-1 and FTC-133. An inverse correlation between CD44s expression and ALDH1 activity was observed in all thyroid cancer cell lines. As for the expressions of CD44 variant isoforms, ACT-1 showed higher and FRO showed moderate CD44v6 expressions, whereas either TPC-1 or FTC-133 showed negative CD44v6 expression. EpCAM expressions in FRO and ACT-1 were higher than those in TPC-1 and FTC-133, and EpCAM expressions inversely correlated with those of CD44s. A positive correlation was observed between EpCAM expression and ALDH1 activity in thyroid cancer cell lines. In the RT-PCR analysis, the expression levels of EpCAM, caludin-7 and ALDH1 in FRO and ATC-1 cells were significantly higher than those in TPC-1 and FTC-133 cells. In clinical specimens of thyroid cancers, nuclear expression of EpCAM and high expression of CD44v6 were detected significantly more frequently in anaplastic carcinomas. CONCLUSIONS/SIGNIFICANCE: Our study suggests the possibility that EpCAM, together with CD44v6 and claudin-7 as well as ALDH1, may be involved in the development of the aggressive phenotype of anaplastic thyroid carcinoma. Our findings may suggest a novel therapeutic strategy for treatment of anaplastic thyroid carcinoma.

NRAS mutations in primary and metastatic melanomas of Japanese patients.
International journal of clinical oncology,19(3):544-8 2014
Author:Hisashi Uhara; Atsuko Ashida; Hiroshi Koga; Eisaku Ogawa; Aya Uchiyama; Ryuhei Uchiyama; Koichi Hayashi; Yukiko Kiniwa; Ryuhei Okuyama
Abstract:BACKGROUND: Characterization of the MAPK signaling pathway in melanoma has led to the development of MEK inhibitors for the treatment of NRAS-mutated melanoma. The success of molecular-targeted therapies underscores the need to identify mutations in target genes. Most of the current data on genetic mutations have been obtained from Caucasian melanoma patients, and screenings of Asian populations are limited. OBJECTIVE: The aim of the present study was to examine NRAS mutations in primary and metastatic lesions of Japanese melanoma patients. METHODS: Clinical melanoma specimens were collected from 127 Japanese patients, including primary (n = 67), metastatic (n = 25) and paired primary and metastatic lesions (n = 35). NRAS mutations in exons 1 and 2 were assessed by polymerase chain reaction and Sanger sequencing. RESULTS: The incidence of NRAS mutations was 7.1 %. NRAS (Q61) was the predominant genetic alteration (77.8 %). NRAS mutations were most frequently detected in acral melanomas (9.3 %), followed by melanomas without chronic sun-induced damage (7.0 %) and mucosal melanomas (4.8 %), and were not detected in melanomas with chronic sun-induced damage. In addition, NRAS mutations were more prevalent in the extremities than in other sites. The NRAS sequence in metastatic lesions did not match that of the primary tumor in one case. CONCLUSION: The frequency of NRAS mutations is lower in the Asian population than in Caucasian patients. The observed heterogeneity of melanoma suggests that genotyping of both primary and metastatic lesions is important to identify candidate patients for molecular-targeted therapies.

Benefit of Proactive Therapy Using Topical Steroid for Atopic Dermatitis-Effect of Twice Weekly Topical Application of 0.05% Betamethasone Butyrate Propionate Ointment-
西日本皮膚科,76(6) 2014
Author:照井正; 木庭幸子; 芦田敦子; 奥山隆平; 小澤麻紀; 相場節也

Combination chemotherapy of carboplatin and paclitaxel for metastatic melanoma.
The Journal of dermatology,40(12):1050-1 2013(Dec.)
Author:Yuki Sato; Hisashi Uhara; Atsuko Ashida; Ryuhei Okuyama

A case of hypocomplementaemic urticarial vasculitis with a high serum level of rheumatoid factor.
The Australasian journal of dermatology,54(3):e62-3 2013(Aug.)
Author:Atsuko Ashida; Hiroshi Murata; Atsuko Ohashi; Eisaku Ogawa; Hisashi Uhara; Ryuhei Okuyama
Abstract:We report a case of hypocomplementaemic urticarial vasculitis with an elevated serum rheumatoid factor level. Hypocomplementaemic urticarial vasculitis is an immune complex-mediated disease characterised by urticarial eruptions. High levels of rheumatoid factor may be associated with hypocomplementaemia due to the consumption of complement, because the rheumatoid factor can form immune complexes with immunoglobulin. It is necessary to pay attention to the amounts of complement in cases of urticarial eruptions with elevated rheumatoid factor level. The eruptions were relieved with a combination of prednisolone and colchicine.

Low p53 positivity in verrucous skin lesion in diabetic neuropathy occurring on the dorsum of the foot
International Journal of Dermatology,52(3):378-380 2013(Mar.)
Author:Atsuko Ashida; Yukiko Kiniwa; Aya Kobayashi; Kazuhiko Matsumoto; Ryuhei Okuyama

日本皮膚科学会雑誌,123(2) 2013
Author:三宅知美; 福沢正男; 藤田幸恵; 松原誠; 大橋敦子; 芦田敦子; 木庭幸子; 宇原久

日本皮膚科学会雑誌,123(2) 2013
Author:木藤健治; 安部学朗; 芦田敦子

Low p53 positivity in verrucous skin lesion in diabetic neuropathy occurring on the dorsum of the foot
Int J Dermatol,52:378-380 2013
Author:Ashida A, Kiniwa Y, Kobayashi A, Matsumoto K, Okuyama R

Focal dermal hypoplasia syndrome(Goltz症候群)の男児例
小児皮膚学会誌,32:83-86 2013

Clinical courses of drug-induced hypersensitivity syndrome treated without systemic corticosteroids.
J Eur Acad Derm Venereol,27:722-726 2013
Author:Uhara H, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R

Case of a cutaneous angiomyolipoma in the ear
JOURNAL OF DERMATOLOGY,39(9):808-809 2012(Sep.)
Author:Yasutomo Mikoshiba; Hiroshi Murata; Atsuko Ashida; Nana Saito; Hiroshi Koga; Hisashi Uhara; Ryuhei Okuyama

Assessment of BRAF and KIT mutations in Japanese melanoma patients
Author:Atsuko Ashida; Hisashi Uhara; Yukiko Kiniwa; Misae Oguchi; Hiroshi Murata; Yasufumi Goto; Aya Uchiyama; Eisaku Ogawa; Koichi Hayashi; Hiroshi Koga; Ryuhei Okuyama

Assessment of BRAF and KIT mutations in Japanese melanoma
J Dermatological Science,66(3):240-242 2012(Jun.)
Author:Ashida A, Uhara H, Kiniwa Y, Oguchi M, Murata H, Goto Y, Uchiyama A, Ogawa E, Hayashi K, Koga H, Okuyama R

A case of epidermolysis bullosa acquisita associated with laryngeal stenosis.
Acta dermato-venereologica,92(1):93-4 2012(Jan.)
Author:Yukiko Kiniwa; Atsuko Ashida; Atsuko Ohashi; Ryosuke Kitoh; Shunpei Fukuda; Takashi Hashimoto; Ryuhei Okuyama

日本乾癬学会学術大会プログラム・抄録集,27th 2012
Author:小川英作; 葭矢裕之; 大橋敦子; 佐藤勇樹; 三宅知美; 小林彩; 芦田敦子; 古賀弘志; 村田浩; 宇原久; 奥山隆平

日本皮膚科学会雑誌,122(4) 2012
Author:斉木実; 宇原久; 河内繁雄; 芦田敦子; 小口真司; 奥山隆平

Case of a cutaneous angiomyolipoma in the ear
J Dermatol,39:808-809 2012
Author:Mikoshiba Y, Murata H, Ashida A, Saito N, Koga H, Uhara H, Okuyama R

Assessment of BRAF and KIT mutations in Japanese melanoma patients
J Dermatol Sci,66::240-242 2012
Author:Ashida A, Uhara H, Kiniwa Y, Oguchi M, Murata H, Goto Y, Uchiyama A, Ogawa E, Hayashi K, Koga H, Okuyama R

Thermal angioedema induced by hot water
Acta Derm Venereol,91:343-344 2011
Author:Kobayashi A, Uhara H, Ashida A, Kiniwa Y, Okuyama R

メシル酸ガベキサートによるEosinophilic panniculitisの1例
皮膚科の臨床,53(12):1783-1785 2011

Skin cancer,25(3):353-357 2011

皮膚病診療,32(7):749-752 2010

NADPH oxidase 4 contributes to transformation phenotype of melanoma cells by regulating G2-M cell cycle progression.
Cancer research,69(6):2647-54 2009(Mar. 15)
Author:Maki Yamaura; Junji Mitsushita; Shuichi Furuta; Yukiko Kiniwa; Atsuko Ashida; Yasuhumi Goto; Wei H Shang; Makoto Kubodera; Masayoshi Kato; Minoru Takata; Toshiaki Saida; Tohru Kamata
Abstract:Generation of reactive oxygen species (ROS) has been implicated in carcinogenic development of melanoma, but the underlying molecular mechanism has not been fully elucidated. We studied the expression and function of the superoxide-generating NADPH oxidase (Nox)4 in human melanoma cells. Nox4 was up-regulated in 13 of 20 melanoma cell lines tested. Silencing of Nox4 expression in melanoma MM-BP cells by small interfering RNAs decreased ROS production and thereby inhibited anchorage-independent cell growth and tumorigenecity in nude mice. Consistently, a general Nox inhibitor, diphenylene iodonium, and antioxidants vitamine E and pyrrolidine dithiocarbamate blocked cell proliferation of MM-BP cells. Flow cytometric analysis indicated that Nox4 small interfering RNAs and diphenylene iodonium induced G(2)-M cell cycle arrest, which was also observed with another melanoma cell line, 928mel. This was accompanied by induction of the Tyr-15 phosphorylated, inactive form of cyclin-dependent kinase 1 (a hallmark of G(2)-M checkpoint) and hyperphosphorylation of cdc25c leading to its increased binding to 14-3-3 proteins. Ectopic expression of catalase, a scavenger of ROS, also caused accumulation of cells in G(2)-M phase. Immunohistochemistry revealed that expression of Nox4 was detected in 31.0% of 13 melanoma patients samples, suggesting the association of Nox4 expression with some steps of melanoma development. The findings suggest that Nox4-generated ROS are required for transformation phenotype of melanoma cells and contribute to melanoma growth through regulation of G(2)-M cell cycle progression.

Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
International journal of cancer,124(4):862-8 2009(Feb. 15)
Author:Atsuko Ashida; Minoru Takata; Hiroshi Murata; Kenji Kido; Toshiaki Saida
Abstract:Recent studies showed KIT gene aberrations in a substantial number of melanomas on acral skin and mucosa, suggesting the therapeutic benefit of tyrosine kinase inhibitors, such as imatinib. We therefore examined the expression and mutations of KIT in 4 primary and 24 metastatic acral and mucosal melanomas. Immunohistochemistry revealed moderate or strong KIT protein expression in 13 (48%) tumors. Sequence analysis revealed K642E and D820Y mutations in two metastases. Amplification of KIT was identified by real-time PCR in 4 tumors, including one that had K642E. Western blot analysis showed phosphorylation of the KIT receptor in 8 (62%) of 13 cryopreserved samples, indicating the frequent pathological activation of the receptor in vivo. Phosphorylation of KIT protein was detected in 2 tumors harboring KIT mutations, as well as in one tumor with KIT gene amplification. Furthermore, 5 tumors without detectable KIT gene aberrations showed phosphorylation of the KIT receptor. Expression of stem cell factor (SCF) in melanoma cells as well as stromal cells suggests SCF/KIT autocrine and paracrine activation in these tumors. Finally, we found significant growth suppressive effects of sunitinib in two acral melanoma cell lines; one harboring the D820Y mutation and one showing SCF-dependent KIT activation. These results show pathological activation of KIT in a substantial number of metastatic tumors of acral and mucosal melanomas, and suggest a potential therapeutic benefit of sunitinib for these melanomas.

日本皮膚病理組織学会抄録集,25th 2009
Author:三宅知美; 中村謙太; 内山龍平; 芦田敦子; 古賀弘志; 林宏一; 上條哲史; 磯部研一; 窪田恵夢; 浅野功治; 上原剛

Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells.
Archives of dermatological research,300(6):297-301 2008(Jul.)
Author:Hitomi Kubo; Atsuko Ashida; Kazuhiko Matsumoto; Toshiro Kageshita; Akifumi Yamamoto; Toshiaki Saida
Abstract:We investigated the anti-tumor effect of human interferon-beta (HuIFN-beta) against malignant melanoma. In vitro study revealed that HuIFN-beta not only inhibited proliferation of melanoma cells (seven cell lines: MM-AN, MM-BP, MM-LH, MM-RU, PM-WK, RPM-EP, RPM-MC) but also induced apoptosis in a dose dependent fashion, though the sensitivity to HuIFN-beta was different among cell lines. In addition, we administered HuIFN-beta into cutaneous metastatic lesions of melanoma and evaluated clinical and histopathological effects. Although the size of the metastatic cutaneous lesion did not change by the intralesional injection of HuIFN-beta, histopathological examination revealed apoptotic changes of melanoma cells along with dense lymphohistiocytic infiltration. The present study confirmed direct and indirect inhibitory effects of HuIFN-beta on human melanoma cells and suggests that local higher concentration of HuIFN-beta is needed to eradicate melanoma lesions.

Establishment of a novel melanoma cell line SMYM-PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas.
Cancer science,98(7):958-63 2007(Jul.)
Author:Hiroshi Murata; Atsuko Ashida; Minoru Takata; Maki Yamaura; Boris C Bastian; Toshiaki Saida
Abstract:We established a novel melanoma cell line, SMYM-PRGP, which was non-tumorigenic in vivo, from an acral melanoma in radial growth phase under a low-oxygen environment. SMYM-PRGP was wild-type for known mutation sites in the BRAF and NRAS genes, and showed focal amplification of the human telomerase reverse transcriptase and cyclin D1 genes as well as the fibroblast growth factor-3 and fibroblast growth factor-4 genes. Neither mutation nor copy number loss of the CDKN2A gene was observed. The p16(INK4A) protein was expressed at a level equal to that in normal melanocytes. Among the various melanocyte growth factors added to the culture of SMYM-PRGP cells, endothelin-1 was the strongest growth stimulator, the effect of which was significantly augmented by the addition of calcium chloride. The growth stimulatory effect of endothelin-1 was shown to be mediated via the endothelin B receptor. The protein level of cyclin D1 in SMYM-PRGP cells was approximately 10 times higher than that in normal melanocytes. Although the stimulation with endothelin-1 plus calcium chloride increased cyclin D1 protein levels after 4-6 h, the level of phosphorylated retinoblastoma protein did not increase, suggesting that overexpression of cyclin D1 protein may have little effect on cell cycle progression but rather act as a pro-survival factor. SMYM-PRGP is an excellent tool for investigating the development and progression of acral melanoma.

旋尾線虫によるcreeping disease
皮膚科の臨床,47(5):749-752 2005

33回日本皮膚悪性腫瘍学会学術大会(秋田) 2017(Jun.)

33回日本皮膚悪性腫瘍学会学術大会(秋田) 2017(Jun.)

116回日皮会総会(仙台) 2017(Jun.)

116回日皮会総会(仙台) 2017(Jun.)

116回日皮会総会(仙台) 2017(Jun.)

193回信州地方会(松本) 2017(Mar.)

Quantitative analysis of the BRAFV600E in circulating tumor-drived DNA using competitive allele-specific TaqMan PCR in melanoma patients
30回表皮細胞研究会≪弘前) 2016(Nov.)

胸水中のcell-free DNAよりBRAFV600Kを検出できた進行期悪性黒色腫の1例
80回東部支部学術大会(浜松) 2016(Oct.)

Evaluation of response to nivolumab treatment in patients with metastatic melanoma using circulating tumor DNA
75回日本癌学会学術総会(横浜) 2016(Oct.)

115回日皮会総会(京都) 2016(Jun.)

幼少期に環状浮腫性紅斑を生じたepidermolysis bullosa simplex with mottled pogmentationの2例
115回日皮会総会(京都) 2016(Jun.)

115回日皮会総会(京都) 2016(Jun.)

79回東京・東部支部合同学術大会(東京) 2016(Feb.)

Epidermal growth factor receptor inhibitor induces tumor necrosis factor-α via activation of the PPARγ and NF-κB from sebocytes
40回日本研究皮膚科学会学術大会総会(岡山) 2015(Dec.)
Presenter:Atsuko Ashida, Eisaku Ogawa, Ryuhei Uchiyama, Hisashi Uhara, Ryuhei Okuyama

Detection of BRAFV600Ecirculating tumor DNA using castPCR in patients with advanced melanoma
74回日本癌学会学術総会(名古屋) 2015(Oct.)
Presenter:Atsuko Ashida, Kaori Sakaizawa, Hisashi Uhara, Ryuhei Okuyama

Familial atypical multiple mole melanoma syndrome
日本臨床 73 増刊6 99-102 2015(Aug.)

188回信州地方会(松本) 2015(Jul.)

114回日皮会総会(横浜) 2015(Apr.)

日本人の悪性黒色腫のBRAF, NRAS, KIT変異率と臨床所見
114回日皮会総会(横浜) 2015(Apr.)

Epidermolysis bullosa simplex with mottled pigmentationの2家系
377回新潟地方会(新潟) 2015(Apr.)

186回信州地方会(松本) 2014(Dec.)

Analysis of EGFR inhibitor-induced inflammation in human sebocytes
28回表皮細胞研究会(鹿児島) 2014(Dec.)

4回群信合同皮膚カンファレンス(長野) 2014(Nov.)

184回信州地方会(松本) 2014(Mar.)

183回信州地方会(松本) 2013(Dec.)

Assessment of NRAS mutation in Japanese melanoma patients
72回日本癌学会学術総会(横浜) 2013(Oct.)

Analysis of EGF receptor(EGFR) inhibitor-induced inflammation in sebaceous cells
4回最新医療研究会(松本) 2013(Sep.)

29回日本皮膚悪性腫瘍学会学術大会(甲府) 2013(Aug.)

日本人のメラノーマ患者における BRAF, NRAS, KITの遺伝子変異の解析
29回日本皮膚悪性腫瘍学会学術大会(甲府) 2013(Aug.)

NRAS mutation in Japanese melanoma patients
8th World Congress of Melanoma(ハンブルグ) 2013(Jul.)
Presenter:Hisashi Uhara, Atsuko Ashida, Aya Uchiyama, Richie Okuyama

182回信州地方会(松本) 2013(Jul.)

182回信州地方会(松本) 2013(Jul.)

181回信州地方会(松本) 2013(Mar.)

180回信州地方会(松本) 2012(Dec.)

Assessment of BRAF and KIT mutations in Japanese melanoma patients
71回日本癌学会学術総会(札幌) 2012(Sep.)

42回 日本皮膚アレルギー接触皮膚炎学会アレルギー学会総会学術大会(軽井沢) 2012(Jul.)

179回信州地方会(松本) 2012(Jul.)

179回信州地方会(松本) 2012(Jul.)

179回信州地方会(松本) 2012(Jul.)

28回日本皮膚悪性腫瘍学会学術大会(札幌) 2012(Jun.)

178回信州地方会(松本) 2012(Mar.)

178回信州地方会(松本) 2012(Mar.)

177回信州地方会(松本) 2011(Dec.)

177回信州地方会(松本) 2011(Dec.)

177回信州地方会(松本) 2011(Dec.)

62回中部支部学術大会(四日市) 2011(Nov.)

75回東部支部学術大会(前橋) 2011(Sep.)

75回東部支部学術大会(前橋) 2011(Sep.)

175回信州地方会(松本) 2011(Jul.)

175回信州地方会(松本) 2011(Jul.)

175回信州地方会(松本) 2011(Jul.)

41回日本皮膚アレルギー接触皮膚炎学会総会学術大会(甲府) 2011(Jul.)

マイコプラズマ感染により発症したStevens Johnson 症候群の1例
41回日本皮膚アレルギー接触皮膚炎学会総会学術大会(甲府) 2011(Jul.)

Skin Cancer,35(3):143-149 2021(Mar.)
Author:二瓶 達也; 芦田 敦子; 翠川 央高; 永井 史緒; 海野 俊徳; 久保 仁美; 住 昌彦; 木庭 幸子; 奥山 隆平

日本皮膚科学会雑誌,131(5):1358-1358 2021
Author:坂井柚季; 芦田敦子; 木庭幸子; 丸山悠太; 重村倫成; 奥山隆平

日本皮膚科学会雑誌,131(5):1213-1213 2021

メラノーマ メラノーマの検査・診断 Liquid biopsy
日本臨床,79(増刊2 皮膚悪性腫瘍(上)):220-224 2021

日本皮膚科学会雑誌,131(3):545-545 2021
Author:中村謙太; 諏訪学; 白井拓史; 面高俊和; 佐野佑; 御子柴育朋; 佐藤勇樹; 三宅知美; 芦田敦子; 木庭幸子; 奥山隆平

肢端型・粘膜型のメラノーマ患者における血漿中のcell-free DNAのコピー数異常を用いた病勢モニタリング
日本皮膚科学会雑誌,131(1):128-128 2021
Author:御子柴飛鳥; 芦田敦子; 木庭幸子; 奥山隆平

Skin dysbiosis occurs in EGFR inhibitor-induced skin rash
日本癌学会学術総会抄録集(Web),79th:PJ3-5 2020
Author:芦田敦子; 冨田秀太; 奧山隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,36th:140-140 2020
Author:中村謙太; 芦田敦子; 木庭幸子; 奥山隆平

皮疹はこう見る,こう表現する よく見る皮膚疾患を発疹レベルで理解する〈良性腫瘍〉脂漏性角化症
Medicina,57(11):1942-1943 2020

日本皮膚科学会雑誌,130(5):1251-1251 2020
Author:白井拓史; 翠川央高; 大澤香奈; 佐野佑; 芦田敦子; 奥山隆平

日本皮膚科学会雑誌,130(5):1247-1247 2020
Author:中村謙太; 芦田敦子; 木庭幸子; 奥山隆平

日本皮膚科学会雑誌,130(3):416-416 2020
Author:中村謙太; 芦田敦子; 木庭幸子; 奥山隆平

日本皮膚科学会雑誌,130(3):416-416 2020
Author:御子柴飛鳥; 芦田敦子; 境澤香里; 奥山隆平

circulating tumor DNA値を参考にencorafenib/binimetinibの用量調整を行った悪性黒色腫の1例
日本皮膚科学会雑誌,130(3):413-413 2020
Author:翠川央高; 佐野佑; 白井拓史; 大澤香奈; 中村謙太; 御子柴飛鳥; 芦田敦子; 木庭幸子; 奥山隆平; 松田順繁

Skin Cancer,33(3):196-200 2019(Feb.)
Author:中村 謙太; 芦田 敦子; 中村 麗那; 木庭 幸子; 奥山 隆平

日本皮膚病理組織学会抄録集,35th:50,31-50,31 2019
Author:皆川茜; 宇原久; 芦田敦子; 境澤香里; 古賀弘志; 奥山隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,35th:160-160 2019
Author:中村謙太; 芦田敦子; 木庭幸子; 奥山隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,35th:113-113 2019
Author:三宅知美; 芦田敦子; 御子柴育朋; 境澤香里; 奥山隆平

日本皮膚科学会雑誌,129(8):1648-1648 2019
Author:諏訪学; 木庭幸子; 芦田敦子; 林宏一; 松本和彦; 奥山隆平; 下島恭弘

日本皮膚科学会雑誌,129(8):1647-1647 2019
Author:芦田敦子; 境澤香里; 奥山隆平; 宇原久

日本皮膚科学会雑誌,129(5):1226-1226 2019
Author:芦田敦子; 関智子; 東里江; 廣田沙也佳; 奥山隆平

日本皮膚科学会雑誌,129(4):592-592 2019
Author:境澤香里; 面高俊和; 三宅知美; 芦田敦子; 奥山隆平

日本皮膚科学会雑誌,129(4):562-562 2019
Author:芦田敦子; 高沢裕子; 関智子; 境澤香里; 羽生田久美子; 上條史尚; 皆川茜; 奥山隆平

緩和ケア実践マニュアル Start Up & Beyond PEACE 症状別緩和ケアスキルBeyond PEACE 皮膚障害-EGFR阻害薬による皮膚障害・手足症候群・がん性皮膚潰瘍・褥瘡
Cancer Board Square,5(1):122-130 2019

日本皮膚科学会雑誌,129(3):394-394 2019
Author:芦田敦子; 代田志保; 奥山隆平; 沼波仁; 木藤健治

新・皮膚科セミナリウム メラノーマの新しい治療法 メラノーマの遺伝子異常
日本皮膚科学会雑誌,128(6):1301-1308 2018(May)
Author:芦田 敦子

日本臨床免疫学会総会プログラム・抄録集,46th:133-133 2018
Author:中村謙太; 芦田敦子; 木庭幸子; 奥山隆平

日本臨床免疫学会総会プログラム・抄録集,46th:105-105 2018
Author:中村謙太; 芦田敦子; 木庭幸子; 奥山隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,34th:154-154 2018
Author:三宅知美; 白井拓史; 芦田敦子; 木庭幸子; 清水晶; 奥山隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,34th:122-122 2018
Author:芦田敦子; 境澤香里; 三宅知美; 御子柴育朋; 奥山隆平

蕁麻疹・痒疹 抗ヒスタミン薬が有効であった日光蕁麻疹の1例
皮膚科の臨床,60(13):1982-1983 2018
Author:大橋敦子; 芦田敦子; 御子柴育朋; 村田浩; 奥山隆平

日本皮膚科学会雑誌,128(2):234-234 2018
Author:諏訪学; 中村謙太; 芦田敦子; 木庭幸子; 奥山隆平

Clinical and genetic characteristics of cutaneous melanoma with clinical history of early childhood onset
Author:A. Minagawa; H. Uhara; K. Sakaizawa; H. Koga; A. Ashida; R. Okuyama

日本癌学会総会記事,76回:P-1351 2017(Sep.)
Author:境澤 香里; 芦田 敦子; 奥山 隆平

日本皮膚科学会雑誌,127(5):1142-1142 2017
Author:御子柴育朋; 佐野佑; 小林彩; 三宅知美; 芦田敦子; 小川英作; 宇原久; 奥山隆平; 杉浦一充

日本皮膚科学会雑誌,127(5):1140-1140 2017
Author:皆川茜; 宇原久; 芦田敦子; 境澤香里; 古賀弘志; 奥山隆平

日本皮膚科学会雑誌,127(5):939-939 2017

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,33rd:160-160 2017
Author:三宅知美; 御子柴育朋; 佐野佑; 白井拓史; 芦田敦子; 古賀弘志; 宇原久; 宇原久; 奥山隆平

BRAF K601E変異メラノーマ~血液循環腫瘍DNAを用いて病勢のモニタリングを行った1例~
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,33rd:146-146 2017
Author:芦田敦子; 境澤香里; 三宅知美; 御子柴育朋; 佐野佑; 白井拓史; 古賀弘志; 奥山隆平

メラノーマ患者におけるcirculating tumor DNAによるニボルマブ治療の評価
日本癌学会総会記事,75回:P-2322 2016(Oct.)
Author:芦田 敦子; 境澤 香里; 宇原 久; 奥山 隆平

Violaceous and Petechial Persistent Plantar Plaques: A Quiz
Author:Atsuko Ashida; Hisashi Uhara; Asuka Mikoshiba; Kaori Sakaizawa; Naomi Kumagai; Hiroshi Koga; Ryuhei Okuyama

A Place for BRAFV600E Mutation-specific Immunohistochemistry Alongside Cell-free DNA Mutation Detection in Melanoma Reply
Author:Atsuko Ashida; Hisashi Uhara; Asuka Mikoshiba; Kaori Sakaizawa; Naomi Kumagai; Hiroshi Koga; Ryuhei Okuyama

日本皮膚科学会雑誌,126(11):2134-2135 2016
Author:中村謙太; 皆川茜; 北澤里美; 芦田敦子; 古賀弘志; 木庭幸子; 宇原久; 奥山隆平

日本皮膚科学会雑誌,126(11):2131-2131 2016
Author:皆川茜; 古賀弘志; 芦田敦子; 奥山隆平; 百瀬正信

日本皮膚科学会雑誌,126(11):2131-2131 2016
Author:面高俊和; 皆川茜; 古賀弘志; 芦田敦子; 宇原久; 奥山隆平

日本皮膚科学会雑誌,126(11):2129-2129 2016
Author:枝光智大; 芦田敦子; 奥山隆平; 春日恵理子; 井出裕一郎

日本皮膚科学会雑誌,126(11):2128-2128 2016
Author:大橋敦子; 芦田敦子; 古賀弘志; 宇原久; 奥山隆平

日本皮膚科学会雑誌,126(11):2127-2127 2016
Author:海野俊徳; 吉川美香; 三宅知美; 小林彩; 内山龍平; 芦田敦子; 奥山隆平

日本臨床免疫学会会誌,39(4):423-423 2016
Author:中村謙太; 芦田敦子; 木庭幸子; 宇原久; 奥山隆平

日本皮膚科学会雑誌,126(7):1306-1306 2016
Author:芦田敦子; 大橋敦子; 奥山隆平; 清水晶

日本皮膚科学会雑誌,126(5):975-975 2016
Author:芦田敦子; 御子柴飛鳥; 熊谷尚美; 境澤香里; 古賀弘志; 宇原久; 奥山隆平

日本皮膚科学会雑誌,126(5):747-747 2016

メラノーマ-基礎から最新薬物療法まで 分子異常
カレントテラピー,34(4):344-349 2016
Author:芦田敦子; 木庭幸子; 宇原久

日本癌学会総会記事,74回:P-3303 2015(Oct.)
Author:芦田 敦子; 境澤 香里; 宇原 久; 奥山 隆平

Clinical Review of Malignant Melanoma Patients Treated at Shinshu University between 2000 and 2009
日本皮膚科学会雑誌,125(8):1587-1592 2015
Author:中村謙太; 皆川茜; 芦田敦子; 古賀弘志; 木庭幸子; 奥山隆平; 宇原久

症候群 Familial atypical multiple mole melanoma syndrome(家族性多発性メラノーマ症候群,家族性異型多発母斑黒色腫症候群)
日本臨床,73(増刊6 家族性腫瘍学):99-102 2015
Author:芦田敦子; 宇原久

治療に伴う有害反応対策 抗EGFR抗体薬による皮膚障害とその予防・対策
日本臨床,73(増刊4 最新臨床大腸癌学):612-616 2015
Author:御子柴飛鳥; 芦田敦子; 奥山隆平

日本皮膚科学会雑誌,125(4):955-955 2015
Author:三宅知美; 芦田敦子; 宇原久; 奥山隆平; 福澤正男; 一瀬白帝

日本皮膚科学会雑誌,125(4):940-940 2015
Author:境澤香里; 芦田敦子; 伊東孝通; 藤澤康弘; 緒方大; 松下茂人; 藤井一恭; 福島聡; 柴山慶継; 八田尚人; 竹之内辰也; 上原治朗; 奥山隆平; 山崎直也; 宇原久

メラノーマ最新情報 日本人におけるMAPK系の遺伝子変異率と遺伝子検査の実際
Monthly Book Derma.,(230):63-68 2015
Author:芦田敦子; 宇原久

皮膚科の臨床,56(13):2169-2172 2014
Author:枝光智大; 芦田敦子; 春日恵理子; 井出裕一郎; 宇原久; 奥山隆平
Abstract:79歳男。重症筋無力症、糖尿病にて加療中であった。2ヵ月前より左足背外側部に紅色皮疹が出現し、近医にて足白癬として抗真菌薬の外用を受けるも改善せず、徐々に隆起してきた。初診時、左足背外側部に鱗屑を有する淡紅色の結節を認め、病理組織学的所見・培養所見よりTricophyton rubrumによる白癬性肉芽腫と診断した。塩酸テルビナフィン内服を開始したところ、2週間後には結節は扁平となり、内服開始5ヵ月経過の現在、結節は瘢痕化している。

日本皮膚科学会雑誌,124(10):1943-1943 2014
Author:宇原久; 境澤香里; 芦田敦子; 奥山隆平

日本皮膚科学会雑誌,124(9):1789-1789 2014
Author:枝光智大; 芦田敦子; 奥山隆平; 春日恵理子; 井出裕一郎

日本皮膚科学会雑誌,124(4):829-829 2014
Author:面高俊和; 皆川茜; 古賀弘志; 芦田敦子; 宇原久; 奥山隆平

日本皮膚科学会雑誌,124(3):358-358 2014
Author:海野俊徳; 浅井裕子; 三宅知美; 吉川美香; 小林彩; 芦田敦子; 奥山隆平

日本皮膚科学会雑誌,124(3):357-357 2014
Author:海野俊徳; 浅井裕子; 葦矢裕之; 吉川美香; 三宅知美; 上條史尚; 佐藤勇樹; 小林彩; 芦田敦子; 村田浩; 奥山隆平

日本皮膚科学会雑誌,124(3):356-356 2014
Author:浅井裕子; 芦田敦子; 岩出舞子; 奥山隆平

日本皮膚科学会雑誌,124(3):355-355 2014
Author:上條史尚; 芦田敦子; 葭矢裕之; 佐藤勇樹; 小林彩; 村田浩; 宇原久; 奥山隆平; 福澤正男

日本皮膚科学会雑誌,124(3):355-355 2014
Author:大橋敦子; 芦田敦子; 村田浩; 宇原久; 奥山隆平; 吉田香奈子

日本皮膚科学会雑誌,124(3):354-354 2014
Author:佐藤勇樹; 葭矢裕之; 御子柴育朋; 芦田敦子; 村田浩; 奥山隆平

Journal of Environmental Dermatology and Cutaneous Allergology,8(1):38-42 2014
Author:上條史尚; 芦田敦子; 葭矢裕之; 佐藤勇樹; 小林彩; 村田浩; 福澤正男; 宇原久; 奥山隆平

日本人の悪性黒色腫患者におけるNRAS遺伝子変異の解析(Assessment of NRAS mutation in Japanese melanoma patients)
日本癌学会総会記事,72回:518-518 2013(Oct.)
Author:芦田 敦子; 宇原 久; 奥山 隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,29th:140-140 2013
Author:大橋敦子; 芦田敦子; 古賀弘志; 宇原久; 奥山隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,29th:137-137 2013
Author:芦田敦子; 宇原久; 奥山隆平

Focal dermal hypoplasia syndrome(Goltz症候群)の男児例
日本小児皮膚科学会雑誌,32(2):173-176 2013
Author:海野俊徳; 芦田敦子; 芦田敦子; 太田由子; 佐野葉子; 奥山隆平

悪性黒色腫 悪性黒色腫の分子生物学 分子生物学:各論 チロシンキナーゼ:KIT
日本臨床,71(増刊4 皮膚悪性腫瘍):134-138 2013
Author:芦田敦子; 木庭幸子; 宇原久; 奥山隆平

悪性黒色腫 悪性黒色腫の分子生物学 分子生物学:各論 MAPキナーゼ経路:NRAS,BRAF,MEK
日本臨床,71(増刊4 皮膚悪性腫瘍):126-129 2013
Author:芦田敦子; 木庭幸子; 宇原久; 奥山隆平

日本皮膚科学会雑誌,123(2):175-175 2013
Author:葭矢裕之; 御子柴育朋; 佐藤勇樹; 芦田敦子; 村田浩; 奥山隆平; 河内繁雄; 土肥庄二郎

日本皮膚科学会雑誌,123(2):174-174 2013
Author:佐藤勇樹; 御子柴育朋; 芦田敦子; 村田浩; 奥山隆平

日本皮膚科学会雑誌,123(2):174-174 2013
Author:御子柴育朋; 村田浩; 赤羽聡子; 佐藤勇樹; 芦田敦子; 宇原久; 奥山隆平

日本皮膚科学会雑誌,123(2):173-173 2013
Author:齊藤奈那; 御子柴育朋; 大橋敦子; 田中飛鳥; 岩出舞子; 芦田敦子; 古賀弘志; 後藤康文; 村田浩; 奥山隆平

日本皮膚科学会雑誌,123(2):173-173 2013
Author:御子柴育朋; 斉藤奈那; 大橋敦子; 芦田敦子; 村田浩; 宇原久; 奥山隆平

日本皮膚科学会雑誌,123(2):173-173 2013
Author:大橋敦子; 御子柴育朋; 芦田敦子; 村田浩; 奥山隆平

日本皮膚科学会雑誌,123(2):172-172 2013
Author:大橋敦子; 芦田敦子; 村田浩; 宇原久; 奥山隆平; 吉田香奈子

日本皮膚科学会雑誌,123(2):171-171 2013
Author:芦田敦子; 大橋敦子; 山浦麻貴; 小川英作; 村田浩; 奥山隆平

日本皮膚科学会雑誌,123(2):171-171 2013
Author:木庭幸子; 大橋敦子; 芦田敦子; 宇原久; 奥山隆平; 小口真司

マイコプラズマ感染により発症したStevens Johnson症候群(SJS)の1例
日本皮膚科学会雑誌,123(2):171-171 2013
Author:御子柴育朋; 大橋敦子; 芦田敦子; 村田浩; 宇原久; 奥山隆平

日本皮膚科学会雑誌,123(2):170-170 2013
Author:芦田敦子; 大橋敦子; 小川英作; 村田浩; 奥山隆平; 斉木実

日本皮膚科学会雑誌,123(2):169-169 2013
Author:小川英作; 大橋敦子; 芦田敦子; 村田浩; 奥山隆平; 牛木淳人

メシル酸ガベキサート(FOY)によるEosinophilic Panniculitisの1例
日本皮膚科学会雑誌,123(2):168-168 2013
Author:芦田敦子; 大橋敦子; 木庭幸子; 奥山隆平

日本人の悪性黒色腫患者におけるBRAF、KIT遺伝子変異の解析(Assessment of BRAF and KIT mutations in Japanese melanoma patients)
日本癌学会総会記事,71回:359-359 2012(Aug.)
Author:芦田 敦子; 宇原 久; 村田 浩; 後藤 康文; 奥山 隆平

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,28回:132-132 2012(Jun.)
Author:葭矢 裕之; 芦田 敦子; 村田 浩; 宇原 久; 奥山 隆平

日本皮膚科学会雑誌,122(2):419-419 2012(Feb.)
Author:芦田 敦子; 小林 彩; 代田 志保; 木庭 幸子; 松本 和彦

日本皮膚科学会雑誌,122(2):418-418 2012(Feb.)
Author:小林 彩; 芦田 敦子; 木庭 幸子; 宇原 久

日本皮膚科学会雑誌,122(2):417-417 2012(Feb.)
Author:中村 謙太; 三宅 知美; 内山 龍平; 太田 桂子; 木藤 健治; 芦田 敦子; 古賀 弘志; 宇原 久; 高田 実; 新倉 冬子

Journal of Environmental Dermatology and Cutaneous Allergology,6(3):274-274 2012
Author:芦田敦子; 佐藤勇樹; 葭矢裕之; 御子柴育朋; 村田浩; 宇原久; 奥山隆平

Journal of Environmental Dermatology and Cutaneous Allergology,6(3):268-268 2012
Author:上條史尚; 芦田敦子; 葭矢裕之; 佐藤勇樹; 小林彩; 村田浩; 宇原久; 奥山隆平; 福澤正男

日本皮膚科学会雑誌,122(9):2336-2336 2012
Author:御子柴育朋; 村田浩; 赤羽聡子; 佐藤勇樹; 芦田敦子; 宇原久; 奥山隆平

皮膚病診療,34(7):683-686 2012
Author:御子柴育朋; 芦田敦子; 村田浩; 宇原久; 奥山隆平

日本皮膚科学会雑誌,122(6):1605-1605 2012
Author:大橋敦子; 御子柴育朋; 芦田敦子; 村田浩; 奥山隆平

日本皮膚科学会雑誌,122(6):1598-1599 2012
Author:御子柴育朋; 斉藤奈那; 大橋敦子; 芦田敦子; 村田浩; 宇原久; 奥山隆平

膵転移を生じたDermatofibrosarcoma protuberans with fibrosarcomatous changeの1例
日本皮膚科学会雑誌,122(4):1231-1231 2012
Author:村田浩; 大橋敦子; 芦田敦子; 奥山隆平; 古澤徳彦; 宮川眞一; 神宮邦彦

皮膚科の臨床,54(2):281-285 2012
Author:三宅知美; 木藤健治; 芦田敦子; 古賀弘志; 林宏一; 斎田俊明; 磯部研一; 窪田恵夢; 浅野功治; 上原剛; 福澤正男; 高田実

日本皮膚科学会雑誌,122(1):107-107 2012
Author:芦田敦子; 小林彩; 代田志保; 木庭幸子; 松本和彦

日本皮膚科学会雑誌,122(1):106-107 2012
Author:小林彩; 芦田敦子; 木庭幸子; 宇原久

日本皮膚科学会雑誌,122(1):106-106 2012
Author:中村謙太; 三宅知美; 内山龍平; 太田桂子; 木藤健治; 芦田敦子; 古賀弘志; 宇原久; 高田実; 新倉冬子

メシル酸ガベキサートによるEosinophilic Panniculitisの1例
皮膚科の臨床,53(12):1783-1785 2011
Author:芦田敦子; 大橋敦子; 木庭幸子; 奥山隆平
Abstract:症例は80歳男性で、左上肢のむくみを主訴とした。2週間前より播種性血管内凝固のためメシル酸ガベキサートを投与中であった。左手から上腕にかけて著明な腫脹を認め、静脈に沿って索状あるいは結節状に皮下硬結を触れる紅斑が広がっていた。同部は熱感とそう痒を伴っていた。血液検査で好酸球増多を認め、皮膚生検で真皮から皮下脂肪織にかけて稠密な好酸球浸潤を認めた。メシル酸ガベキサートによるeosinophilic panniculitisと診断し、プレドニゾロンの全身投与を開始したところ、翌日から症状が著明に改善した。その後、再燃は認めなかった。

Focal dermal hypoplasia syndrome(Goltz syndrome)の1例
日本皮膚科学会雑誌,121(14):3392-3392 2011
Author:芦田敦子; 太田由子; 佐野葉子

Journal of Environmental Dermatology and Cutaneous Allergology,5(3):268-268 2011
Author:御子柴育朋; 大橋敦子; 芦田敦子; 村田浩; 宇原久; 奥山隆平

Journal of Environmental Dermatology and Cutaneous Allergology,5(3):268-268 2011
Author:小川英作; 大橋敦子; 芦田敦子; 村田浩; 奥山隆平; 牛木淳人

メシル酸ガベキサート(FOY)によるEosinophilic Panniculitis
日本皮膚科学会雑誌,121(5):924-924 2011
Author:芦田敦子; 大橋敦子; 木庭幸子; 奥山隆平

日本皮膚科学会雑誌,121(4):752-752 2011
Author:大橋敦子; 芦田敦子; 木庭幸子; 奥山隆平

Verrucous skin lesion on the feet in diabetic neuropathyの1例
日本皮膚科学会雑誌,121(3):627-627 2011
Author:芦田敦子; 大橋敦子; 木庭幸子; 松本和彦; 奥山隆平

日本皮膚科学会雑誌,121(3):585-585 2011
Author:木庭幸子; 大橋敦子; 芦田敦子; 宇原久; 鬼頭良輔; 福田俊平; 橋本隆; 奥山隆平

A case of melanocyte-specific protein-negative melanoma of unknown origin
Skin Cancer,25(3):353-357 2011
Author:木庭幸子; 芦田敦子; 高沢裕子; 大橋敦子; 後藤康文; 礒部研一; 奥山隆平
Abstract:69歳、男性。2007年に背部軟部腫瘍を近医で切除され、原発巣不明の転移性腫瘍と診断された。翌年1月には右側胸部に皮下転移が生じ、さらに右腋窩リンパ節と右鎖骨動脈周囲リンパ節、背部皮下と右上腕皮下にも転移が出現した。当院整形外科で軟部肉腫に準じた化学療法が行われ、2009年1月に広汎腫瘍切除術とリンパ節郭清術が施行された。病理組織学的に類上皮様の大型の腫瘍細胞が密に増殖し、S-100陽性、CK AE1/AE3陰性、EMA陰性、HMB-45陰性、MART-1陰性であることから、類上皮型の悪性末梢神経鞘腫瘍と診断された。術後に化学療法と放射線療法が行われたが、副腎転移が出現し両側副腎摘出が行われた。さらに皮下転移が出現したため、同年11月に当科を紹介された。当科紹介時に血清5-S-CDが高値を示したので、過去の組織を用いて免疫染色を行った。腫瘍細胞はMITFとHMW-MAAが陽性であることから、本性例を悪性黒色腫と確定診断を下すに至った。(著者抄録)

日本皮膚悪性腫瘍学会学術大会プログラム・抄録集,26回:193-193 2010(Jun.)
Author:木庭 幸子; 大橋 敦子; 高沢 裕子; 芦田 敦子; 後藤 康文; 奥山 隆平

皮膚病診療,32(7):749-752 2010
Author:塩原順子; 芦田敦子; 久保仁美; 高田実; 福澤正男
Abstract:<症例のポイント>直腸(肛門管)原発無色素性悪性黒色腫、所属リンパ節および多発性肺転移の54歳男性例。ダカルバジンとインターフェロンβ併用療法中に多発脳転移を生じた。原発巣にKIT遺伝子D820Y変異が検出され、用量を調節し2コース投与した。スニチニブの効果判定はprogressive diseaseであった。KIT変異を有する肢端部や粘膜原発の悪性黒色腫に対して、イマチニブまたはスニチニブを用いた分子標的治療が可能である。分子標的治療の適応の決定と薬剤の選択には、転移巣の遺伝子解析が必要である。(著者抄録)

日本皮膚病理組織学会会誌,25(2):61-61 2010
Author:三宅知美; 中村謙太; 内山龍平; 芦田敦子; 古賀弘志; 林宏一; 上條哲史; 磯部研一; 窪田恵夢; 浅野功治; 上原剛

ステロイドの全身投与なしで軽快したDrug-induced hypersensitivity syndrome(DIHS)
日本皮膚科学会雑誌,120(2):276-277 2010
Author:芦田敦子; 三宅知美; 内山龍平; 木藤健治; 古賀弘志; 高田実

日本皮膚科学会雑誌,120(1):75-75 2010
Author:塩原順子; 芦田敦子; 久保仁美; 高田実; 福沢正男

NADPH oxidase(Nox)4によるG2-M細胞周期進行の新しい調節機構(A Novel link of NADPH oxidase(Nox)4 redox-signaling to G2-M cell cycle progression in melanoma cell proliferation)
日本生化学会大会プログラム・講演要旨集,82回:3T10a-5 2009(Sep.)
Author:山浦 真貴; 満下 淳地; 古田 秀一; 木庭 幸子; 芦田 敦子; 後藤 泰文; 加藤 真良; 高田 実; 斎田 敏明; 鎌田 徹

メラノーマでは、RAS/RAF/MEK/ERKシグナルはcyclin D、cyclin Eの双方を制御する(Both cyclin D and cyclin E are downstream targets of the RAS/RAF/MEK/ERK pathway in melanoma cells)
日本癌学会総会記事,68回:485-486 2009(Aug.)
Author:村田 浩; 芦田 敦子; 後藤 康文; 木藤 健治; 高田 実

転移性肢端型・粘膜型黒色腫では野生型KITが活性化している(Pathological activation of wild-type KIT is common in metastatic tumors of acral and mucosal melanomas)
日本癌学会総会記事,67回:222-222 2008(Sep.)
Author:芦田 敦子; 村田 浩; 木藤 健治; 高田 実; 斎田 俊明

日本皮膚科学会雑誌,118(7):1273-1273 2008
Author:小川香里; 芦田敦子; 河内繁雄; 高田実; 斎田俊明

異なる進展段階から樹立された肢端黒色腫細胞株におけるMAPK経路の活性化とMEK阻害剤U0126の効果(Activation of the MAPK pathway, and growth inhibitory effect of a MEK inhibitor, U0126, in acral melanoma cell lines)
日本癌学会総会記事,66回:527-528 2007(Aug.)
Author:芦田 敦子; 村田 浩; 木藤 健治; 高田 実; 斎田 俊明

日本研究皮膚科学会年次学術大会・総会プログラム,32回:156-156 2007(Apr.)
Author:芦田 敦子; 村田 浩; 高沢 裕子; 高田 実; 斎田 俊明

Cyclin D1遺伝子増幅を示す新しい肢端黒色腫細胞株(SMYM-PRGP)のシグナル伝達経路の解析
日本研究皮膚科学会年次学術大会・総会プログラム,31回:157-157 2006(Apr.)
Author:村田 浩; 高田 実; 芦田 敦子; 高木 裕子; 山浦 麻貴; 斎田 俊明

日本皮膚科学会雑誌,116(3):353-353 2006
Author:小川香里; 高木裕子; 井出葉子; 芦田敦子; 河内繁雄

水平増殖期末端黒子型悪性黒色腫細胞株の樹立とその性質の解析(Establishment and characterization of a cell line derived from the radial growth phase acral melanoma)
日本癌学会総会記事,64回:206-206 2005(Sep.)
Author:村田 浩; 芦田 敦子; 高田 実; 斎田 俊明

Creeping Disease Due to Spirurid Nematode Larva
皮膚科の臨床,47(5):749-752 2005
Author:芦田敦子; 河内繁雄; 斎田俊明; 高本雅哉; 赤尾信明
Abstract:51歳男.生ホタルイカの自家製沖漬けを大量に食した2週間後,そう痒と熱感を伴った浮腫性紅斑と移動する線状疹が出現した.Creeping diseaseが疑われ,線状皮疹の浸潤を触れる先端部を中心に皮下まで切除したところ,皮疹先端よりやや先の部分に相当する表皮直下に虫体横断面が認められた.虫体の通過部位と思われる部位には好酸球の集積が著明であった.旋尾線虫幼虫タイプXと同定し,虫体摘出後にステロイド軟膏外用を行い皮疹は消退した.タイプX幼虫の薄切切片を抗原とした酵素抗体法による血中抗体検査では,患者血清200倍希釈まで陽性であった

旋尾線虫幼虫によるcreeping diseaseの1例
日本皮膚科学会雑誌,114(7):1315-1315 2004
Author:芦田敦子; 河内繁雄; 高本雅哉; 赤尾信明

日本皮膚科学会雑誌,113(10):1590-1590 2003(Sep.)
Author:芦田 敦子; 河内 繁雄; 斎田 俊明

CD30陽性cutaneous large T cell lymphoma
日本皮膚科学会雑誌,113(5):815-815 2003
Author:吉沢さえ子; 太田桂子; 宮崎敦; 芦田敦子; 六波羅詩穂; 宇原久; 斎田俊明

日本皮膚科学会雑誌,110(7):1145-1145 2000
Author:芦田敦子; 斎田俊明

ゆう状外観を呈する皮膚病 臨床例 1 温熱性紅斑上に生じたthermal keratosis 慢性ひ素中毒症の合併が疑われた症例
皮膚病診療,22(5):421-424 2000
Author:芦田敦子; 松永るり; 林宏一; 斎田俊明
Abstract:症例は68歳女で,左前腕の淡紅褐色局面(A),腹部の網状色素沈着(B),前腕の角化性淡紅色皮疹(C),下腿の角化性局面(D),手背の疣状皮疹(E)など多彩な症状を呈した.幼少時よりこたつを使用しており,寒がりのため20歳頃からはほぼ1年中電気ごたつと上掛け電気毛布を使用していた.臨床・病理組織学的所見よりAはBowen病,B温熱性紅斑,C・Dはthermal keratosisと診断した.Eについては,全身性瀰漫性の色素沈着や小白斑の存在より慢性砒素中毒症を考えた.患者に対し電気毛布・こたつの温度を低くし部屋全体を暖めるよう指導した.角化性病変には定期的に液体窒素療法を行い徐々に軽快しているが,色素沈着に変化はみられていない

thermal keratosisを合併し慢性砒素中毒症が疑われた1例
日本皮膚科学会雑誌,109(8):1246-1246 1999(Jul.)
Author:芦田 敦子; 松永 るり; 林 宏一; 河内 繁雄; 斎田 俊明

日本皮膚科学会雑誌,109(8):1245-1245 1999(Jul.)
Author:松永 るり; 芦田 敦子; 林 宏一; 宇原 久; 斎田 俊明; 渡辺 朋美; 佐藤 新司; 井上 廣司

日本皮膚科学会雑誌,109(8):1246-1247 1999(Jul.)
Author:林 宏一; 松永 るり; 芦田 敦子; 宇原 久; 斎田 俊明

日本皮膚科学会雑誌,109(8):1244-1244 1999(Jul.)
Author:芦田 敦子; 金児 みわ子; 斎田 俊明

Skin Cancer,14(2):220-224 1999
Author:林宏一; 松永るり; 芦田敦子; 宇原久; 斎田俊明; 安達亙; 梶川昌二; 渡辺智文
Abstract:症例は48歳の女性で上腹部の鈍痛を自覚して受診し,肝腫大とLDHの高値を指摘された.大腸ファイバー検査で肛門管に約15cmの結節が認められた.生検により悪性黒色腫と診断され,腹部CTで肝転移が認められた.患者と相談の上,生命予後,QOLを考慮し,できるだけ負担の少ない治療としてシスプラチン単剤の肝動注を選択した.初回の治療でperformance statusとLDH値に急速な改善がみられたため,皮下にリザーバーを留置した.経皮的な薬剤投与が可能になり,動注時の患者負担を軽減できた.しかし,全身状態が不良なため肺炎を併発し死亡した

日本皮膚科学会雑誌,108(8):1086-1086 1998(Jul.)
Author:松永 るり; 芦田 敦子; 林 宏一; 宇原 久; 斎田 俊明; 渡辺 朋美; 佐藤 新司; 井上 廣司

Sclerodermatous Chronic GVHD(Graft-versus-host Disease).
皮膚科の臨床,40(4):641-644 1998
Author:芦田敦子; 松本和彦; 小池健一; 斎田俊明

日本皮膚科学会雑誌,107(11):1415-1415 1997(Oct.)
Author:芦田 敦子

日本皮膚科学会雑誌,107(11):1419-1419 1997(Oct.)
Author:芦田 敦子

A case of infantile fibrosarcoma arising in the abdominal skin.
臨床皮膚科,51(6):467-469 1997
Author:芦田敦子; 大久保幸子; 渡辺朋美; 土肥庄二郎; 斎田俊明